# Transitioning Between Treprostinil Formulations: Evidence and Strategies

**Authors:** Megan Clarke, Ali Ataya, Alison M. Turkin, Raj Parikh, Kyle Davis, Chad E. Miller, Alexander Kantorovich, Thomas Winkler, Steven J. Cassady

PMC · DOI: 10.1007/s12325-025-03401-6 · 2025-11-10

## TL;DR

This review summarizes evidence on transitioning between different forms of treprostinil, a drug used to treat pulmonary hypertension, highlighting the need for personalized strategies.

## Contribution

The paper consolidates existing evidence to guide clinicians on transitioning between treprostinil formulations with a focus on individualized approaches.

## Key findings

- Over 100 patients were studied, with crossover strategies being the most common transition method.
- Approximately 80% of transitions were successful, though success criteria varied across studies.
- Unsuccessful transitions were often due to disease progression or therapy intolerance.

## Abstract

Treprostinil is a prostacyclin analog available in four formulations: parenteral, oral, inhalation solution, and inhalation powder. All formulations of treprostinil are indicated for the treatment of pulmonary arterial hypertension; the inhaled formulations are also approved for pulmonary hypertension associated with interstitial lung disease. Transitions between formulations are frequent in clinical practice but lack standardized guidance. This review summarizes published evidence regarding safety, efficacy, and techniques of transitioning between treprostinil formulations. The evidence includes over 100 patients across various settings, with crossover transition strategies most frequently employed. Approximately 80% of cases reviewed were deemed successful; however, it should be noted there was no standardized definition for success across publications. Unsuccessful transitions were often linked to disease progression or intolerance to therapy. These findings underscore the importance of individualized transition strategies, informed by clinical status, patient preferences, and formulation-specific pharmacokinetics. By consolidating the current evidence, this review aims to support clinicians in optimizing transitions and maintaining continuity of treprostinil therapy.

Graphical abstract available for this article.

## Linked entities

- **Chemicals:** treprostinil (PubChem CID 54786)
- **Diseases:** pulmonary arterial hypertension (MONDO:0015924), pulmonary hypertension (MONDO:0005149), interstitial lung disease (MONDO:0015925)

## Full-text entities

- **Diseases:** interstitial lung disease (MESH:D017563), pulmonary hypertension (MESH:D006976), pulmonary arterial hypertension (MESH:D000081029)
- **Chemicals:** Treprostinil (MESH:C427248), prostacyclin (MESH:D011464)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12858517/full.md

---
Source: https://tomesphere.com/paper/PMC12858517